期刊文献+

近期上市的经皮给药制剂 被引量:8

Recent advances of marketed transdermal preparations
原文传递
导出
摘要 现代经皮给药制剂的概念、内涵和应用范围已突破传统的皮肤用药,它包括透皮给药系统(TDDS)和皮肤局部外用制剂,可以用于治疗全身性疾病或皮肤局部疾病。本文按剂型特点综述近年国外上市的多种经皮给药制剂产品。 Compared with the traditional skin medication, the modern transdermal preparations have already been developed with new concept and broad application scope. Modern transdermal preparations including transdermal drug delivery system (TDDS) and topical external preparations can be used to treat systemic disease or topical skin disease. According to formulation specificity, the transdermal preparations marketed in recent years are comprehensively and systematically reviewed in this paper.
出处 《世界临床药物》 CAS 2012年第8期496-502,共7页 World Clinical Drug
基金 国家"重大新药创制"科技重大专项(2012ZX09304004)
关键词 经皮给药制剂 透皮给药系统 局部外用制剂 transdermal preparation transdermal drug delivery system topical external preparation
  • 相关文献

参考文献32

  • 1Duggan ST, Curran MP. Transdermal granisetron [J]. Drugs, 2009, 69 (18): 2597-2605. 被引量:1
  • 2Tuca A. Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review[J]. Cancer Manag Res, 2009, 2 (1) : 1-12. 被引量:1
  • 3Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis[J]. Curt Med Res Opin, 2010, 26 (2) : 263-269. 被引量:1
  • 4Plosker GL. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non- malignant pain [J]. Drugs, 2011, 71 (18) : 2491-2509. 被引量:1
  • 5Steiner D J, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study[ J]. J Pain Symptom Manage, 2011, 42 (6) : 903-917. 被引量:1
  • 6Watson Pharma. ANDRODERM (testosterone transdermal system), for topical use [EB/OL]. http://www.accessdata.fda. gov/drugsatfda_docs/label/2012/020489s0271bl.pdf. 被引量:1
  • 7Senesh G, Bushi D, Neta A, et al. Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump [J]. J Diabetes Sci Technol, 2010,4(1): 104-110. 被引量:1
  • 8Ebert CD, Sanders SW. Compositions and methods for transdermal oxybutynin therapy: US, 71794832007 [P]. 2007-02-20. 被引量:1
  • 9Dmochowski PR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference [J]. Clin Drug Investig, 2011, 31 (8): 559-571. 被引量:1
  • 10Antares Pharma. ANTUROL (oxybutynin) gel 3% for topical use [EB/OL]. http://www.accessdata.fda.gov/ drugsatfda_docs/label/2011/202513 s0001bl.pdf. 被引量:1

同被引文献95

引证文献8

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部